CRL - Charles River Laboratories International, Inc.

NYSE - NYSE Delayed Price. Currency in USD

Charles River Laboratories International, Inc.

251 Ballardvale Street
Wilmington, MA 01887
United States
781-222-6000
http://www.criver.com

SectorHealthcare
IndustryDiagnostics & Research
Full Time Employees14,700

Key Executives

NameTitlePayExercisedYear Born
Mr. James C. FosterChairman, CEO & Pres4.52M4.37M1951
Mr. David Ross SmithCorp. Exec. VP & CFO1.36M1.38M1966
Mr. David P. JohstCorp. Exec. VP, HR, Gen. Counsel & Chief Admin. Officer1.93M1.79M1962
Mr. William D. BarboChief Commercial Officer & Corp. Exec. VP1.01MN/A1961
Ms. Birgit GirshickCorp. EVP of Discovery & Safety Assessment, Biologics Testing Solutions and Avian Vaccine Services957.35k218.17k1970
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves biopharmaceutical companies; biotechnology, agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic, and consumer product companies; contract research and contract manufacturing organizations; other commercial entities; and hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Corporate Governance

Charles River Laboratories International, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 3. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 4; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.